p38丝裂原活化蛋白激酶阻滞剂SB203580对白血病K562细胞周期的作用及机制  

Effect of p38 MAPK pathway inhibitors SB203580 on cell cycle of leukemia K562 cell lines and its mechanisms

作　　者：郭晓[1] 董春杰[2] 宋丹[1] 李文静[1] 潘岐[3] 

机构地区：[1]白求恩国际和平医院血液科,石家庄050082 [2]白求恩国际和平医院消化内科,石家庄050082 [3]河北医科大学第二医院血液科

出　　处：《白血病．淋巴瘤》2009年第8期449-451,共3页Journal of Leukemia & Lymphoma

摘　　要：目的研究p38丝裂原活化蛋白激酶（MAPK）阻滞剂SB203580对K562细胞周期的作用及机制。方法以反转录-聚合酶链反应（RT—PCR）和Western blotting方法检测SB203580处理K562细胞后p38、CyclinD2、Cyclin E、p27mRNA和蛋白的表达并以流式细胞术（FCM）检测其细胞周期的变化。结果SB203580处理后K562细胞p38、CyclinD2、Cyclin E mRNA和蛋白表达降低；p27mRNA和蛋白表达增高。G0／G1期细胞增多，S期细胞减少，与用药前相比差异均有统计学意义。结论SB203580可能通过p38途径，影响细胞周期调控蛋白，最终抑制K562细胞的增生。Objective To study the effect of p38 mitogen activated protein kinase （MAPK） pathway inhibitors SB203580 on cell cycle of K562 cell lines and its mechanisms. Methods The expression of mRNA and protein of p38,Cyclin D2,Cyclin E and P27 in K562 cell lines treated with SB203580 were detected by retrotranscription polymerase chain reaction （RT-PCR） and Western blotting, respectively. Cell cycle was determined by flow eytometry （FCM）. Results The expressions of mRNA and protein of p38, Cyclin D2 and Cyclin E in K562 cell lines treated with SB203580 were decreased and the expression of p27 was increased.The percentage of cells in G0/G1 phase was increased and was decreased in S phase. There was a significant difference as compared with K562 cell lines before treated with SB203580. Conclusion SB203580 can affect cell cycle regulatory proteins by p38 pathway and eventually inhibit proliferation of K562 cells.

关 键 词：白血病 细胞周期 P38丝裂原活化蛋白激酶类 K562细胞 SB203580 

分 类 号：R285.5[医药卫生—中药学]